(AOF) – Quantum Genomics has announced the strengthening of industrial property around aminopeptidase A inhibitors with the issuance of new patents protecting its second drug candidate, QGC606. The United States Patent and Trademark Office (USPTO) has transmitted its agreement to grant a patent resulting from the application filed on September 10, 2021. The Australian Patent Office has validated the grant of patent AU2020235216 without modification of the application filed on August 17, 2021.
These two new patents protect in the United States and Australia until March 2040, a new chemical series of cerebral aminopeptidase A inhibitors and more particularly the drug candidate QGC606, as well as any pharmaceutical composition comprising one of these inhibitors as active principle, for therapeutic use in the treatment of cardiovascular pathologies.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.